Fulcrum Therapeutics

OverviewSuggest Edit

The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
TypePublic
Founded2016
HQCambridge, US
Websitefulcrumtx.com

Latest Updates

Employees (est.) (Feb 2020)73(+18%)
Job Openings9
Share Price (Oct 2020)$10.9 (+9%)
Cybersecurity ratingBMore

Key People/Management at Fulcrum Therapeutics

Robert J. Gould

Robert J. Gould

President and Chief Executive Officer, Board Member
Owen Wallace

Owen Wallace

Chief Scientific Officer
Pamela S. Strode

Pamela S. Strode

Senior Vice President, Regulatory Affairs and Quality Assurance
Diego Cadavid

Diego Cadavid

Senior Vice President, Clinical Development
Christopher Moxham

Christopher Moxham

Senior Vice President, Discovery
Lucienne Ronco

Lucienne Ronco

Vice President, Translational Medicine
Show more

Fulcrum Therapeutics Office Locations

Fulcrum Therapeutics has an office in Cambridge
Cambridge, US (HQ)
26 Landsdowne St
Show all (1)

Fulcrum Therapeutics Financials and Metrics

Fulcrum Therapeutics Revenue

USD

Revenue (Q2, 2020)

2.0m

Net income (Q2, 2020)

(15.7m)

EBIT (Q2, 2020)

(15.9m)

Market capitalization (16-Oct-2020)

300.1m

Closing stock price (16-Oct-2020)

10.9

Cash (30-Jun-2020)

75.7m
Fulcrum Therapeutics's current market capitalization is $300.1 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

4.5m8.3m13.1m

R&D expense

18.5m25.2m71.1m

Operating expense total

23.0m33.5m84.2m

EBIT

(23.0m)(33.5m)(84.2m)
Quarterly
USDQ2, 2019Q1, 2020Q2, 2020

Revenue

750.0k2.0m

General and administrative expense

2.6m5.1m5.1m

R&D expense

10.9m14.5m12.8m

Operating expense total

13.5m19.5m17.9m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

407.0k72.8m96.7m

Prepaid Expenses

931.0k1.3m3.4m

Current Assets

1.3m74.1m100.1m

PP&E

2.9m10.5m9.2m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.6m101.6m25.4m75.7m

Prepaid Expenses

1.7m3.6m2.8m2.3m

Current Assets

51.4m105.2m84.3m134.8m

PP&E

10.0m9.6m9.4m8.9m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(23.0m)(32.6m)(82.7m)

Depreciation and Amortization

715.0k1.3m2.1m

Accounts Payable

208.0k(20.0k)803.0k

Cash From Operating Activities

(20.1m)(22.6m)(39.5m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(50.0m)(66.6m)(18.5m)(34.1m)

Depreciation and Amortization

1.0m1.5m539.0k1.1m

Accounts Payable

451.0k2.8m1.4m1.4m

Cash From Operating Activities

(22.0m)(35.0m)(15.2m)(29.3m)
USDFY, 2017

Financial Leverage

3.3 x
Show all financial metrics

Fulcrum Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Fulcrum Therapeutics Online and Social Media Presence

Embed Graph

Fulcrum Therapeutics News and Updates

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) --  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Investigational New Drug application (IND) is now i…

Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the company’s ongoing stu…

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

– Conference call scheduled for 8:00 a.m. ET today –

Fulcrum Therapeutics Completes $68.5 Million Private Placement

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced the closing of a $68.5 million private placement pursuant to a securities purchase agreement with a group of institutional investors and accredited investors.

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results

Conference call scheduled for 8:00 a.m. ET today Conference call scheduled for 8:00 a.m. ET today

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Thursday, March 5, 2020 at 8:00 a.m. ET

CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2019 financial results …
Show more

Fulcrum Therapeutics Blogs

Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform

Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform Content Import Thu, 05/21/2020 - 07:00 Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Hig…

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results

Conference call scheduled for 8:00 a.m. ET today CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC) , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business

Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the

Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2020 financial results will be released

Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease

CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it is on track for submission of an Investigational New Drug

Fulcrum Therapeutics Provides Business Update on Impact of COVID-19

CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update in the context of the developing situation
Show more

Fulcrum Therapeutics Frequently Asked Questions

  • When was Fulcrum Therapeutics founded?

    Fulcrum Therapeutics was founded in 2016.

  • Who are Fulcrum Therapeutics key executives?

    Fulcrum Therapeutics's key executives are Robert J. Gould, Owen Wallace and Pamela S. Strode.

  • How many employees does Fulcrum Therapeutics have?

    Fulcrum Therapeutics has 73 employees.

  • Who are Fulcrum Therapeutics competitors?

    Competitors of Fulcrum Therapeutics include Metacrine, Yumanity Therapeutics and PamBio.

  • Where is Fulcrum Therapeutics headquarters?

    Fulcrum Therapeutics headquarters is located at 26 Landsdowne St, Cambridge.

  • Where are Fulcrum Therapeutics offices?

    Fulcrum Therapeutics has an office in Cambridge.

  • How many offices does Fulcrum Therapeutics have?

    Fulcrum Therapeutics has 1 office.